跳至主要内容
临床试验/IRCT20090117001556N120
IRCT20090117001556N120招募中3 期

Effect of Spirinolactone as an Adjuvant Therapy on Improvement of Negative Signe and Cognitive Symptoms in Schizophrenic Patients ; A randomized, double-blind clinical trial with placebo control

Tehran University of Medical Sciences0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 50 years(—)
性别
All

入选标准

  • Diagnosis of Schizophrenia based on DSM-5 criteria
  • Age between 18-50
  • Chronic Schizophrenia- duration of the disorder more than 2 years
  • Minimum score of 19 in negative sub score

排除标准

  • Any serious medical or neurological problem
  • IQ less than 70
  • Substance dependence during the last 6 months(except for nicotine and caffeine)
  • Receiving ECT during the last 2 weeks
  • Serum potassium more than 5 meq/L
  • History of cardiosurgery
  • Receiving oral antipsychotics during the last week or long-standing antipsychotic during the last month
  • Meeting the criteria of major depressive disorder
  • Suicidality
  • Concurrent consumption of alcohol
  • Pregnant or lactating women
  • Receiving Pentoxifylline

研究者

相似试验